Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 in Non-hospitalized Adults With Acute Respiratory Syncytial Virus Infection Who Are at High Risk for Complications
NCT05568706Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoints: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms and Time to Complete Resolution of LRTD Symptoms. Started Nov 2022; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05568706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568706.